- Home
- TRIN vs OCS Comparison
TRIN vs OCS Comparison
Compare TRIN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIN
- OCS
- Stock Information
- Founded
- TRIN 2007
- OCS 2003
- Country
- TRIN United States
- OCS Switzerland
- Employees
- TRIN N/A
- OCS N/A
- Industry
- TRIN Finance/Investors Services
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- TRIN Finance
- OCS Health Care
- Exchange
- TRIN Nasdaq
- OCS Nasdaq
- Market Cap
- TRIN 974.3M
- OCS 956.4M
- IPO Year
- TRIN 2021
- OCS N/A
- Fundamental
- Price
- TRIN $14.96
- OCS $17.73
- Analyst Decision
- TRIN Hold
- OCS Strong Buy
- Analyst Count
- TRIN 3
- OCS 3
- Target Price
- TRIN $15.17
- OCS $35.33
- AVG Volume (30 Days)
- TRIN 751.2K
- OCS 13.7K
- Earning Date
- TRIN 08-06-2025
- OCS 08-26-2025
- Dividend Yield
- TRIN 13.64%
- OCS N/A
- EPS Growth
- TRIN 37.77
- OCS N/A
- EPS
- TRIN 2.19
- OCS N/A
- Revenue
- TRIN $240,010,000.00
- OCS $847,333.00
- Revenue This Year
- TRIN $24.11
- OCS $10.23
- Revenue Next Year
- TRIN $4.87
- OCS $912.87
- P/E Ratio
- TRIN $6.83
- OCS N/A
- Revenue Growth
- TRIN 30.65
- OCS N/A
- 52 Week Low
- TRIN $12.50
- OCS $10.79
- 52 Week High
- TRIN $16.82
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- TRIN 59.21
- OCS 41.73
- Support Level
- TRIN $14.58
- OCS $17.53
- Resistance Level
- TRIN $15.14
- OCS $18.57
- Average True Range (ATR)
- TRIN 0.22
- OCS 0.56
- MACD
- TRIN 0.02
- OCS 0.01
- Stochastic Oscillator
- TRIN 77.99
- OCS 30.39
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.